Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Table 3

Subgroup analysis for the prognostic value of sST2 on all-cause mortality.

Subgroups	All-cause mortality
		HR (95% CI)	value	Heterogeneity; (%),
Overall	8	2.05 (1.51-2.78)	<0.001	81.6%, ≤0.001
Treatment
Dialysis	6	2.72 (1.65-4.49)	≤0.001	83.0%, ≤0.001
Predialysis	1	1.41 (1.22-1.63)	≤0.001	—
Txp	1	1.36 (1.00-1.85)	0.050	—
Continent
Europe and America	4	1.63 (1.29-2.06)	≤0.001	66.4%, 0.038
Asia	4	3.53 (1.17-10.66)	0.025	89.5%, ≤0.001
DM proportion
<Median percentage	4	1.59 (1.14-2.24)	0.007	53.2%, 0.093
≥Median percentage	4	2.60 (1.51-4.47)	0.001	90.1%, ≤0.001
Sample size
<400	4	2.11 (1.26-3.53)	0.005	55.1%, 0.083
≥400	4	2.08 (1.35-3.20)	0.001	90.4%, ≤0.001

, number of studies; HR: hazard ratio; CI: confidence interval; Txp: transplant patients; DM: diabetes mellitus.